Comparative efficacy of brigatinib and alectinib in ALK-rearrangement advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis of phase3 randomized trials
Not Applicable
Completed
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000036861
- Lead Sponsor
- Showa University School of Medicine, Department of Medicine, Division of Respiratory Medicine and Allergology,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 785
Inclusion Criteria
Not provided
Exclusion Criteria
Studies of patients with double cancer, immunecompromised patients, patients of poor performance status, and patients previously treated with ALT-TKIs
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method